文献速递呼吸危重症与机械通气

重新审视ARDS中的允许性高碳酸血症:叙述性综述

Re-examining Permissive Hypercapnia in ARDS: A Narrative Review.
PubMed 文献 · Chest · 2017-11-22

肺保护性通气(LPV)是ARDS治疗的基石,部分患者无法耐受LPV而出现显著CO2升高,此时采用允许性高碳酸血症。本文为叙述性综述,汇总动物模型与临床研究中高碳酸血症的终末器官效应,探讨CO2升高与急性肺心病及ICU死亡率的关联,并简要回顾中重度ARDS中正在研究的CO2管理替代疗法。

要点

  • 允许性高碳酸血症虽被认为良性,但CO2升高具有显著的生理效应
  • 需关注高碳酸血症的终末器官效应及其与急性肺心病、ICU死亡率的关联
  • 中重度ARDS的CO2管理替代疗法尚在研究中

核心结论

  • 允许性高碳酸血症并非无害,CO2升高具有显著的生理效应,需重新审视其在ARDS中的应用。

研究设计与样本

  • 叙述性综述,汇总动物模型与临床研究中高碳酸血症相关的终末器官效应。

主要发现

  • CO2升高具有显著的生理效应,综述探讨了其与急性肺心病及ICU死亡率的关联。

临床怎么用

  • 对无法耐受肺保护性通气而出现显著CO2升高的ARDS患者,应关注高碳酸血症的终末器官效应及急性肺心病风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lung-protective ventilation (LPV) has become the cornerstone of management in patients with ARDS. A subset of patients is unable to tolerate LPV without significant CO2 elevation. In these patients, permissive hypercapnia is used. Although thought to be benign, it is becoming increasingly evident that elevated CO2 levels have significant physiological effects. In this narrative review, we highlight clinically relevant end-organ effects in both animal models and clinical studies. We also explore the association between elevated CO2, acute cor pulmonale, and ICU mortality. We conclude with a brief review of alternative therapies for CO2 management currently under investigation in patients with moderate to severe ARDS.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Barnes T, Zochios V, Parhar K, et al. Re-examining Permissive Hypercapnia in ARDS: A Narrative Review. Chest. 2017. PMID: 29175086. doi:10.1016/j.chest.2017.11.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。